Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth
PARIS, Sept. 17, 2007--Sanofi-aventis today made
announced it plans to have 31 potential submissions by the end of
2010. The company released a detailed analysis on its
Significant progress in pipeline
§ Important clinical results and 31 potential submissions by the end of 2010.
§ 48 projects in advanced phases (phase IIb/III).
§ A well balanced portfolio between our major therapeutic areas.
High-potential projects in our spheres of excellence
Possible successor to Lovenox® and an alternative to antivitamin K
AVE5026 (new ultra low molecular weight heparin): Phase IIb results demonstrated potentially greater efficacy than Lovenox® with a comparable safety profile. Large-scale phase III program to start. Anticoagulant with best-in-class potential.
Biotinylated idraparinux (selective, neutralizable factor Xa synthetic inhibitor): Comparative study versus anti-vitamin K due to start at end 2007 targeting a major clinical need in anti-coagulation – prevention of stroke and systemic embolism in cases of atrial fibrillation.
A portfolio that targets all stages of the disease while offering relevant solutions for concomittant comorbidities, in particular overweight
Rimonabant (the first CB1 antagonist): Significant expansion of the clinical program in type 2 diabetes, with more than 5,700 patients, including a comparative study versus the most recently-approved type 2 diabetes treatment due to start in the first quarter of 2008. Worldwide submission in this indication scheduled for 2009.
AVE0010 (GLP-1 agonist): Very encouraging phase IIb results. Once a day injection demonstrated efficacy. Start of a phase III program in the first half of 2008. Prolonged release formulation due to start phase II trials in the first half of 2008.
AVE2268 (SGLT-2 inhibitor): Ideal profile for use in combination with other anti-diabetics. Phase IIb results due in the first half of 2008, followed by rapid start of phase III.
Please see the attachment for the complete press release.
Tel (33) 1 53 77 44 50
Fax (33) 1 53 77 46 22
Posted: September 2007